215 related articles for article (PubMed ID: 25656882)
1. PD-1 inhibitors effective in hodgkin lymphoma.
Cancer Discov; 2015 Feb; 5(2):102-3. PubMed ID: 25656882
[No Abstract] [Full Text] [Related]
2. [Not Available].
Bounaix L; Bendouda M; Bay JO; Lemal R
Bull Cancer; 2016 Nov; 103 Suppl 1():S160-S163. PubMed ID: 28057180
[TBL] [Abstract][Full Text] [Related]
3. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
Villasboas JC; Ansell S
Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
[TBL] [Abstract][Full Text] [Related]
4. Checkpoint Inhibition in Hodgkin Lymphoma - a Review.
Bröckelmann PJ; Engert A
Oncol Res Treat; 2017; 40(11):654-660. PubMed ID: 29065424
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint inhibitors in Hodgkin's lymphoma.
Jezeršek Novaković B
Eur J Haematol; 2016 Apr; 96(4):335-43. PubMed ID: 26560962
[TBL] [Abstract][Full Text] [Related]
6. PD-1 Blockers.
Wolchok JD
Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
[TBL] [Abstract][Full Text] [Related]
7. Clinical Trials of PD-1 and PD-L1 inhibitors in NSCLC.
Clin Adv Hematol Oncol; 2014 Jan; 12(1 Suppl 1):14-6. PubMed ID: 24852398
[No Abstract] [Full Text] [Related]
8. Programmed death protein 1 inhibitors making inroads in multiple cancers.
Brower V
J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25957444
[No Abstract] [Full Text] [Related]
9. Targeting Immune System Alterations in Hodgkin Lymphoma.
Grover NS; Savoldo B
Curr Hematol Malig Rep; 2017 Aug; 12(4):358-369. PubMed ID: 28780614
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab for classical Hodgkin's lymphoma.
Burki TK
Lancet Oncol; 2016 Aug; 17(8):e324. PubMed ID: 27397043
[No Abstract] [Full Text] [Related]
11. Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma.
Ansell SM
Lancet Haematol; 2019 Jan; 6(1):e2-e3. PubMed ID: 30612711
[No Abstract] [Full Text] [Related]
12. Program death inhibitors in classical Hodgkin's lymphoma: a comprehensive review.
Dada R
Ann Hematol; 2018 Apr; 97(4):555-561. PubMed ID: 29322203
[TBL] [Abstract][Full Text] [Related]
13. PD-1 Blockade in Mediastinal Gray-Zone Lymphoma.
Melani C; Major A; Schowinsky J; Roschewski M; Pittaluga S; Jaffe ES; Pack SD; Abdullaev Z; Ahlman MA; Kwak JJ; Morgan R; Rabinovitch R; Pan Z; Haverkos BM; Gutman JA; Pollyea DA; Smith CA; Wilson WH; Kamdar M
N Engl J Med; 2017 Jul; 377(1):89-91. PubMed ID: 28679093
[No Abstract] [Full Text] [Related]
14. Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma.
Cheah CY; Fowler NH; Neelapu SS
Curr Opin Oncol; 2015 Sep; 27(5):384-91. PubMed ID: 26248256
[TBL] [Abstract][Full Text] [Related]
15. Challenges to Biomarker Testing for PD-1/PD-L1 Checkpoint Inhibitors for Lung Cancer.
Cagle PT; Bernicker EH
Arch Pathol Lab Med; 2015 Dec; 139(12):1477-8. PubMed ID: 26619015
[No Abstract] [Full Text] [Related]
16. Where Do Programmed Death-1 Inhibitors Fit in the Management of Malignant Lymphoma?
Ansell SM
J Oncol Pract; 2016 Feb; 12(2):101-6. PubMed ID: 26869644
[TBL] [Abstract][Full Text] [Related]
17. PD-1 inhibitor approved for melanoma.
Cancer Discov; 2014 Nov; 4(11):1249. PubMed ID: 25367933
[No Abstract] [Full Text] [Related]
18. Immunotherapy for melanoma using programmed death 1 checkpoint inhibitors.
Hamid O
Clin Adv Hematol Oncol; 2014 Nov; 12(11):782-4. PubMed ID: 25674719
[No Abstract] [Full Text] [Related]
19. PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher.
Allen PB; Gordon LI
Expert Rev Hematol; 2016 Oct; 9(10):939-49. PubMed ID: 27622603
[TBL] [Abstract][Full Text] [Related]
20. Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin's lymphoma.
Lee JJ; Chan A; Tang T
Acta Oncol; 2016; 55(4):519-20. PubMed ID: 26754959
[No Abstract] [Full Text] [Related]
[Next] [New Search]